BOSTON ( TheStreet) -- Welcome to the Biotech Stock Mailbag: Memorial Day 2010 edition.Preston M. kicks things off, asking, " Adam, I appreciate your critical eye when it comes to evaluating drug stocks. What do you think of Neostem (NBS), which seems to be doing quite well these days and is generating a lot of buzz? Thanks." To learn about Neostem -- and to understand why I'd be wary about sinking investment dollars into the company -- read Neostem's most recent 10-K annual report filed with the Securities and Exchange Commission. Read the SEC filing first -- before you visit Neostem's web site, before you read the company's press releases, and before you visit the stock message boards.
|ASCO Stocks to Watch 13 ASCO Stocks Presenting New Clinical Data|